Patent intelligence · US
US 11529298
Cosmetic composition and its use, dermocosmetic formulation
Cosmetic composition and its use, dermocosmetic formulation
Patent details — US 11529298
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 20, 2022
- Expiration
- Dec 15, 2042
- Applicant
- LUXBIOTECH FARMACÉUTICA LTDA
- Claims
- 24
- CPC classes
- A61K, A61K2800/522, A61K2800/524, A61K2800/59
Quick answer
US 11529298 (Cosmetic composition and its use, dermocosmetic formulation) is held by LUXBIOTECH FARMACÉUTICA LTDA. Status: granted. Granted Dec 20, 2022. Expires Dec 15, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- LUXBIOTECH FARMACÉUTICA LTDA
- Grant date
- Expiration
- Claims
- 24
- CPC classes
- A61K, A61K2800/522, A61K2800/524, A61K2800/59, A61K8/19, A61K8/34
More from LUXBIOTECH FARMACÉUTICA LTDA
Related pharmaceutical patents in our USPTO index.
-
US 12116405
Arthritis treatment
granted -
US 11932688
Treatment for neoplastic diseases
granted -
US 11773157
Compositions and methods for treating and preventing Staphylococcus aureus infections
granted -
US 11523981
Cosmetic composition and its use, dermocosmetic formulation
granted -
US 11370831
Compositions and methods for treating and preventing Staphylococcus aureus infections
granted -
US 10577410
Compositions and methods for treating and preventing Staphylococcus aureus infections
granted -
US 10294296
Treatment for neoplastic diseases
granted
Frequently asked questions
What is US patent 11529298?
US 11529298 (Cosmetic composition and its use, dermocosmetic formulation) is held by LUXBIOTECH FARMACÉUTICA LTDA. Status: granted. Granted Dec 20, 2022. Expires Dec 15, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11529298?
LUXBIOTECH FARMACÉUTICA LTDA is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 31 pharmaceutical patents for this assignee.
When does US 11529298 expire?
Our index shows an expiration date of Dec 15, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.